Polymorphically acetylated aminoglutethimide in humans

R. C. Coombes; A. B. Foster; S. J. Harland; M. Jarman; E. C. Nice

doi:10.1038/bjc.1982.209

Polymorphically acetylated aminoglutethimide in humans

R. C. Coombes, A. B. Foster, S. J. Harland, M. Jarman, E. C. Nice

Research output: Contribution to journal › Article › Research › peer-review

3 Citations (Scopus)

Abstract

The urinary excretion during 24 h of aminoglutethimide (AG) its major metabolite (N-acetylAG) and two minor metabolites (N-formylAG and nitroG) were measured in 10 volunteers given AG who had been typed for acetylator phenotype using sulphadimidine. The slow acetylators of sulphadimidine excreted more AG (mean 28% of the administered dose) than did the fast acetylators (12%), but the latter excreted more of the dose as N-acetylAG (8.8%) than did the former (3.9%). NitroG and N-formylAG were minor urinary metabolites of AG in humans. The former was more abundant in the urine of slow acetylators (0.10% of the dose) than in that of fast acetylators (0.047%), whereas the respective proportions of doses excreted as the N-formyl derivative (0.475 and 0.465%) were not significantly different for the two acetylator phenotypes. These results show that AG is among those drugs that are polymorphically acetylated in humans.

Original language	English
Pages (from-to)	340-345
Number of pages	6
Journal	British Journal of Cancer
Volume	46
Issue number	3
DOIs	https://doi.org/10.1038/bjc.1982.209
Publication status	Published - 1 Jan 1982
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.1982.209

Cite this

@article{8a1290b0c29d429997482463299ff774,

title = "Polymorphically acetylated aminoglutethimide in humans",

abstract = "The urinary excretion during 24 h of aminoglutethimide (AG) its major metabolite (N-acetylAG) and two minor metabolites (N-formylAG and nitroG) were measured in 10 volunteers given AG who had been typed for acetylator phenotype using sulphadimidine. The slow acetylators of sulphadimidine excreted more AG (mean 28% of the administered dose) than did the fast acetylators (12%), but the latter excreted more of the dose as N-acetylAG (8.8%) than did the former (3.9%). NitroG and N-formylAG were minor urinary metabolites of AG in humans. The former was more abundant in the urine of slow acetylators (0.10% of the dose) than in that of fast acetylators (0.047%), whereas the respective proportions of doses excreted as the N-formyl derivative (0.475 and 0.465%) were not significantly different for the two acetylator phenotypes. These results show that AG is among those drugs that are polymorphically acetylated in humans.",

author = "Coombes, {R. C.} and Foster, {A. B.} and Harland, {S. J.} and M. Jarman and Nice, {E. C.}",

year = "1982",

month = jan,

day = "1",

doi = "10.1038/bjc.1982.209",

language = "English",

volume = "46",

pages = "340--345",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Polymorphically acetylated aminoglutethimide in humans

AU - Coombes, R. C.

AU - Foster, A. B.

AU - Harland, S. J.

AU - Jarman, M.

AU - Nice, E. C.

PY - 1982/1/1

Y1 - 1982/1/1

N2 - The urinary excretion during 24 h of aminoglutethimide (AG) its major metabolite (N-acetylAG) and two minor metabolites (N-formylAG and nitroG) were measured in 10 volunteers given AG who had been typed for acetylator phenotype using sulphadimidine. The slow acetylators of sulphadimidine excreted more AG (mean 28% of the administered dose) than did the fast acetylators (12%), but the latter excreted more of the dose as N-acetylAG (8.8%) than did the former (3.9%). NitroG and N-formylAG were minor urinary metabolites of AG in humans. The former was more abundant in the urine of slow acetylators (0.10% of the dose) than in that of fast acetylators (0.047%), whereas the respective proportions of doses excreted as the N-formyl derivative (0.475 and 0.465%) were not significantly different for the two acetylator phenotypes. These results show that AG is among those drugs that are polymorphically acetylated in humans.

AB - The urinary excretion during 24 h of aminoglutethimide (AG) its major metabolite (N-acetylAG) and two minor metabolites (N-formylAG and nitroG) were measured in 10 volunteers given AG who had been typed for acetylator phenotype using sulphadimidine. The slow acetylators of sulphadimidine excreted more AG (mean 28% of the administered dose) than did the fast acetylators (12%), but the latter excreted more of the dose as N-acetylAG (8.8%) than did the former (3.9%). NitroG and N-formylAG were minor urinary metabolites of AG in humans. The former was more abundant in the urine of slow acetylators (0.10% of the dose) than in that of fast acetylators (0.047%), whereas the respective proportions of doses excreted as the N-formyl derivative (0.475 and 0.465%) were not significantly different for the two acetylator phenotypes. These results show that AG is among those drugs that are polymorphically acetylated in humans.

UR - http://www.scopus.com/inward/record.url?scp=0019977994&partnerID=8YFLogxK

U2 - 10.1038/bjc.1982.209

DO - 10.1038/bjc.1982.209

M3 - Article

C2 - 7126424

AN - SCOPUS:0019977994

SN - 0007-0920

VL - 46

SP - 340

EP - 345

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 3

ER -

Polymorphically acetylated aminoglutethimide in humans

Abstract

UN SDGs

Access to Document

Other files and links

Cite this